Search
News
Press releases
Contact
Work with us
About us
Idea and vision
Management Team
Board of Directors
Scientific Advisory Board
Technology
Abiprot® Antibody Discovery Platform
Scientific publications
Portfolio
Pipeline
Programs
Corporate Governance
ANNUAL GENERAL MEETING 2023
Rights issue 2023
Previous General Meetings
Board of Directors and Management
Nomination Committee
Articles of Association
Investor Relations
Financial Reports
Annual Reports for the years 2016–2022
Convertible bonds rights issue 2022
Investor Relations contact
Partnering
Partnership & Collaboration
Press releases
2023
Oblique Therapeutics offentliggör prospekt med anledning av förestående företrädesemission
Oblique Therapeutics genomför en företrädesemission om 63,5 msek
Oblique Therapeutics förlänger teckningsperioden i pågående företrädesemission
Oblique Therapeutics offentliggör utfall i genomförd företrädesemission
2022
Oblique Therapeutics informerar om konvertering av tvingande konvertibler
Oblique Therapeutics is delighted to announce the appointment of Christer Nordstedt M.D. PhD. as Chief Executive Officer
Oblique Therapeutics offentliggör utfall i företrädesemission av tvingande konvertibler
Oblique Therapeutics forläander teckningsperiod i den pågående företrädesemissionen av tvingande konvertibler
Oblique Therapeutics is pleased to announce that the United States Patent and Trademark Office has granted a patent for its innovative AbiProt® technology
2021
Oblique Therapeutics is thrilled to strengthen its commercial teams to realize its ambitious goals
Oblique Therapeutics announces achievement of key milestone in its aKRAS-mAb program and Abiprot® platform
Science Advances publishes proteomics technology from Oblique Therapeutics AB with a potential to bring several novel antibody medicines to large patient populations in multiple disease areas
Science Advances publicerar artikel om proteomikteknik från Oblique Therapeutics AB som kan bidra till utveckling av nya antikroppsläkemedel till stora patientpopulationer inom flera sjukdomsområden
Oblique Therapeutics is excited to present the recent progress on its anti-Thioredoxin mAb program at the annual meeting of Society for Immunotherapy of Cancer, Nov 10 – 14, Washington DC, USA.
2020
Oblique Therapeutics AB has identified a potentially important epitope for generation of SARS-CoV-2 antibodies
Oblique Therapeutics AB raises 98 MSEK in a private placement investment round
Oblique Therapeutics together with collaborators at Sahlgrenska University Hospital and Karolinska Institutet has been granted 5MSEK by Vinnova
Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms
2019
Oblique Therapeutics has been recognized as one of the 15 most promising Biotech startups in Europe 2019, by StartUp City magazine
Oblique Therapeutics will be presenting at the Inaugural RAS-Targeted Drug Discovery Europe Summit in Vienna in February 2020
2018
Science Translational Medicine publishes research results from Oblique Therapeutics and Karolinska Institute on a new treatment
Oblique Therapeutics present tumor growth inhibition and Treglowering data for OT1096 congress ESMO
